Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.”In the company’s words, NCT00794716 on ClinicalTrials.gov
- Main trialPhase 2
- “This study is to evaluate the predictive value of NRL972 pharmacokinetics in the diagnosis of steatohepatitis using fatty liver disease as the comparator group. In addition, the sensitivity and specificity of NRL972 pharmacokinetics as a diagnostic tool will be compared to results from the standard laboratory tests, elastography, tests of metabolic markers and serum fibrosis markers frequently used in the evaluation of clinically predicted NAFLD patients. Patients will be included if they have clinical evidence of fatty liver disease and have been referred to the clinic for a diagnostic…”In the company’s words, NCT00794716 on ClinicalTrials.gov
- Other names
- cholyl-lysyl-fluorescein
Other drugs for Non-Alcoholic Fatty Liver Disease
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
- Efimosfermin AlfaGSK · Phase 3
- PegozaferminHoffmann-La Roche · 89bio, Inc. · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- SemaglutideNovo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | Mar 2010 | PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026